We are live on ! Find out more
AVEO

AVEO Pharmaceuticals

Delisted

AVEO was delisted on the 19th of January, 2023.

70 hedge funds and large institutions have $60M invested in AVEO Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.11% more ownership

Funds ownership: 57.93% → 63.04% (+5.1%)

0% more call options, than puts

Call options by funds: $6K | Put options by funds: $6K

0% less capital inflows, than outflows

Capital inflows: $15.3M | Capital outflows: $15.4M

14% less funds holding

Funds holding: 81 → 70 (-11)

18% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 28

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

57% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 21

Holders
70
Holders Change
-11
Holders Change %
-13.58%
% of All Funds
2.03%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
9
Increased
23
Reduced
28
Closed
21
Calls
$6​K
Puts
$6​K
Net Calls
–
Net Calls Change
+$181​K

AVEO Hedge Fund Activity: Q4 2013 in Review

70 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals (AVEO) for Q4 2013, worth a combined $60M — down 3.1% from $62M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of AVEO and 9 opened new positions — a net loss of 12 holders — while 28 trimmed existing stakes and 23 added.

The largest buyer was Great Point Partners, opening a new position worth an estimated $6.01M. The largest seller was Palo Alto Investors, cutting an estimated $4.17M.

  • 70 institutional investors held AVEO Pharmaceuticals (AVEO) as of Q4 2013, down from 81 in Q3 2013.
  • Funds reported $60M of AVEO Pharmaceuticals stock for Q4 2013, down 3.1% quarter-over-quarter.
  • 9 funds opened new AVEO Pharmaceuticals positions in Q4 2013 and 21 closed out, a net change of -12 holders.
  • The largest AVEO Pharmaceuticals buyer in Q4 2013 was Great Point Partners, an estimated $6.01M added.
  • The largest AVEO Pharmaceuticals seller in Q4 2013 was Palo Alto Investors, an estimated $4.17M sold.

Based on aggregated 13F filings for Q4 2013.